Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Meeting Report From the 2025 Cure Ocular Melanoma (CURE OM) Global Science Meeting, Amsterdam, the Netherlands, October 2025.

Pigment cell & melanoma research·2026
Same author

Identifying the drivers of genetic risk in patients with multiple primary melanoma.

The Journal of investigative dermatology·2026
Same author

Radiation therapy, cytogenetic prognostication, novel systemic chemotherapy, and patient perspective in an adult with choroidal melanoma.

CA: a cancer journal for clinicians·2026
Same author

Preclinical response of uveal melanomas to the velcrin compound, BAY 2666605.

Molecular cancer therapeutics·2026
Same author

Identification of MITF-regulated transcript isoforms of ubiquitously expressed genes.

The Journal of investigative dermatology·2026
Same author

UV induces common cutaneous amyloid-like melanosomal protein aggregates.

bioRxiv : the preprint server for biology·2025

Related Experiment Video

Updated: May 12, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Targeting melanoma by small molecules: challenges ahead.

Rizwan Haq1, David E Fisher

  • 1Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.

Pigment Cell & Melanoma Research
|April 25, 2013
PubMed
Summary

Small molecule inhibitors show promise for melanoma treatment, but current screening methods have limitations. Refining these screening approaches is crucial for discovering more effective melanoma drugs.

More Related Videos

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

A Melanoma Patient-Derived Xenograft Model
07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

Related Experiment Videos

Last Updated: May 12, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

A Melanoma Patient-Derived Xenograft Model
07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

Area of Science:

  • Oncology
  • Pharmacology
  • Drug Discovery

Background:

  • Targeting melanoma with small molecule inhibitors has advanced cancer treatment.
  • Existing screening approaches for melanoma drug discovery face significant limitations.
  • Further innovation is needed to overcome current challenges in melanoma therapy.

Purpose of the Study:

  • To review the historical screening methodologies used in melanoma research.
  • To identify and discuss the limitations of current screening models.
  • To propose refined screening strategies for enhanced small molecule inhibitor discovery.

Main Methods:

  • Historical review of melanoma screening techniques.
  • Critical analysis of the efficacy and drawbacks of past and present methods.
  • Conceptualization of novel screening paradigms.

Main Results:

  • Current screening approaches have inherent limitations hindering efficient drug discovery.
  • A historical perspective reveals the evolution and shortcomings of melanoma targeting strategies.
  • Proposed refinements aim to improve the predictive power of screening models.

Conclusions:

  • Refining screening models is essential for accelerating the development of effective small molecule inhibitors for melanoma.
  • Addressing the limitations of current methods will improve the success rate of melanoma drug discovery.
  • Enhanced screening strategies hold promise for future melanoma patient treatments.